New molecular entities/new biologics - Xolair - Omalizumab - Genetech/Novartis/Tanox - First biologic approved for the treatment of allergic asthma

被引：0
|
作者：
不详
机构：
来源：
FORMULARY | 2003年 / 38卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：392 / +
页数：2
相关论文
共 9 条
  • [1] Omalizumab (Xolair®) first anti-IgE antibody for treatment of poorly controlled severe persistent allergic asthma
    Pierre, Jacques
    PRESSE MEDICALE, 2007, 36 (03): : 444 - 444
  • [2] Assessment of New Molecular Entities Approved for Cancer Treatment in 2020
    Smith, Claire E. P.
    Prasad, Vinay
    JAMA NETWORK OPEN, 2021, 4 (05)
  • [3] Xolair: A New Monoclonal Drug Anti-IgE Antibody for the Treatment of Allergic Asthma
    Di Domenico, Monica
    Polverino, Mario
    De Rosa, Concetta
    Ricci, Vilma
    Bisogno, Angelica
    Capasso, Anna
    BIOMEDICAL RESEARCH-INDIA, 2011, 22 (01): : 111 - 119
  • [4] Trends in the Safety of New Molecular Entities and Therapeutic Biologics Approved by the FDA (1980-2014)
    Seoane-Vazquez, Enrique
    Rodriguez-Monguio, Rosa
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 : 477 - 478
  • [5] New molecular entities/new biologics - FluMist - Intranasal influenza virus vaccine, live - Medimmune/Wyeth - First nasally delivered flu vaccine approved
    不详
    FORMULARY, 2003, 38 (07) : 395 - +
  • [6] Anti-IgE monoclonal antibody, omalizumab: a new treatment for allergic asthma
    Chung, KF
    EXPERT OPINION ON PHARMACOTHERAPY, 2004, 5 (02) : 439 - 446
  • [7] New molecular entities/new biologics - Boniva - Ibandronate - Roche/Glaxosmithkline - Treatment and prevention of osteoporosis
    不详
    FORMULARY, 2003, 38 (07) : 392 - 392
  • [8] Postmarketing Safety-Related Regulatory Actions for New Therapeutic Biologics Approved in the United States 2002-2014: Similarities and Differences With New Molecular Entities
    Bulatao, Ilynn
    Pinnow, Ellen
    Day, Brendan
    Cherkaoui, Sanae
    Kalaria, Manish
    Brajovic, Sonja
    Dal Pan, Gerald
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 108 (06) : 1243 - 1253
  • [9] Representation of Women and Minorities in Clinical Trials for New Molecular Entities and Original Therapeutic Biologics Approved by FDA CDER from 2013 to 2015
    Chen, Alice
    Wright, Hilary
    Itana, Hawi
    Elahi, Merina
    Igun, Ayomide
    Soon, Guoxing
    Pariser, Anne R.
    Fadiran, Emmanuel O.
    JOURNAL OF WOMENS HEALTH, 2018, 27 (04) : 418 - 429
1